"This is the time they should deliver RT because cells in S phase is most sensitive to radiation because RT cuts replicating DNA double helix at many many places and cells cannot repair very well in S phase. You should not take T for a day or two after RT is delivered because again T would arrest cells to allow the time to repair DNA damage. All oncologists know this, but they don't apply the knowledge in trials, most likely because of the constraint imposed on the control patients who should get the best standard care. You may recall ASCO-reported fantastic synergy between Erbitux and RT in treating head & neck tumors"
Yet another reason to like YMI. David Allen the CEO of YMI is pushing their egf'r drug with radiation in phase 3 H&N, GBM, and phase 2 nsclc and pancreatic. YMI"s phase 2 results in H&N where similiar to the results seen by erbitux with a smaller radiation doseage.
Any thoughts on how a egf'r drug with a attached radiation molecule will perform if the theory above is correct. YMI has one in phase II trials in Italy for GBM's.
Also one more thing I would like input on. Is there any reason not to feel overly optimistic on tesmilifen. 50% improvement in life extension in all patients first phase 3. 142% improvement in life extension for those with mets within the first 3 years of diagnosis. The only drug to show life extension in the last 30 years for breast cancer is herceptin and these results seem much better then herception which only extended life by 33% in 25% of patients. I really would like to hear a few concerns on this drug.
Thanks,
Randy
Market Data 
Markets 
AI
